Standard BioTools Adds Two Directors to Board

TL;DR

Standard BioTools adds Rothberg & Harding to board, signaling potential strategic shifts.

AI Summary

Standard BioTools Inc. announced on June 27, 2024, the election of two new directors, Dr. Jonathan M. Rothberg and Mr. David E. R. Harding, to its Board of Directors. This move is part of the company's ongoing efforts to strengthen its governance and strategic direction.

Why It Matters

The addition of experienced directors like Dr. Rothberg and Mr. Harding could signal a strategic shift or enhanced focus on innovation and growth for Standard BioTools.

Risk Assessment

Risk Level: low — The filing reports routine board appointments, which typically carry low immediate risk.

Key Players & Entities

• Standard BioTools Inc. (company) — Registrant
• Dr. Jonathan M. Rothberg (person) — Newly elected director
• Mr. David E. R. Harding (person) — Newly elected director
• June 27, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share LAB Nasdaq Global Select Ma

Filing Documents

• tm2418585d1_8k.htm (8-K) — 37KB
• tm2418585d1_ex10-1.htm (EX-10.1) — 122KB
• 0001104659-24-076823.txt ( ) — 353KB
• lab-20240627.xsd (EX-101.SCH) — 3KB
• lab-20240627_lab.xml (EX-101.LAB) — 33KB
• lab-20240627_pre.xml (EX-101.PRE) — 22KB
• tm2418585d1_8k_htm.xml (XML) — 4KB

02. Departure of Directors or Certain Officers; Election

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Standard BioTools Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on June 27, 2024. The Company's stockholders voted to approve an amendment to the Company's Amended and Restated 2011 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of common stock reserved for issuance thereunder by 19,125,000 shares. The Plan is described in further detail in the Company's definitive proxy statement on Schedule 14A for the Annual Meeting filed with the Securities and Exchange Commission on May 21, 2024, as supplemented on June 3, 2024 (the "Proxy Statement"), which description is incorporated herein by reference. The complete text of the Plan is set forth in Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

07. Submission of Matters to a Vote

Item 5.07. Submission of Matters to a Vote of Security Holders. On May 16, 2024 (the "Record Date"), the Company had 369,920,511 shares of common stock issued and outstanding. A total of 292,959,945 votes, or approximately 79.19% of the total voting power of the shares of the Company's capital stock issued and outstanding and entitled to vote at the Annual Meeting were represented in person or by proxy at the Annual Meeting. The following proposals are described in detail in the Proxy Statement. The final voting results for each of the matters submitted to a stockholder vote at the Annual Meeting are set forth below: 1. Election of Class II Directors. The following nominees were elected to serve as Class II directors, to hold office until the Company's 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Troy Cox 222,829,923 7,618,480 62,511,542 Fenel M. Eloi 221,580,993 8,868,410 62,510,542 2. Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2023 was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 200,835,452 28,960,018 653,932 62,510,543 3. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 was approved by the following vote: Votes For Votes Against Abstentions 291,606,384 383,526 970,035 4. Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan. The proposal to approve the amendment to the Plan to increase the shares of common stock reserved thereunder by 19,125,000 shares was approve

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 10.1+ Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan, As Amended. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). +Management compensation plan or arrangement. 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 1, 2024 STANDARD BIOTOOLS INC. By: /s/ Jeffrey Black Name: Jeffrey Black Title: Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR